133 related articles for article (PubMed ID: 11407306)
21. Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice.
del Real G; Llorente M; Boscá L; Hortelano S; Serrano A; Lucas P; Gómez L; Torán JL; Redondo C; Martínez C
AIDS; 1998 May; 12(8):865-72. PubMed ID: 9631139
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages.
Dahlén E; Andersson M; Dawe K; Tellander AC; Brunmark C; Björk A; Hedlund G
Autoimmunity; 2000 Oct; 32(3):199-211. PubMed ID: 11092700
[TBL] [Abstract][Full Text] [Related]
23. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
24. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
25. Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation.
Peltoniemi J; Setälä N; Broberg E; Röyttä M; Hukkanen V; Salmi AA; Erälinna JP
J Neuroimmunol; 2002 Nov; 132(1-2):83-92. PubMed ID: 12417437
[TBL] [Abstract][Full Text] [Related]
26. Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells.
Xiao BG; Bail XF; Zhang GX; Hedlund G; Link H
Neurosci Lett; 1998 Jun; 249(1):17-20. PubMed ID: 9672378
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy.
Peltoniemi J; Broberg EK; Nygårdas M; Erälinna JP; Waris M; Hukkanen V
Int Immunopharmacol; 2006 May; 6(5):817-29. PubMed ID: 16546713
[TBL] [Abstract][Full Text] [Related]
28. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis.
Zhang GX; Yu LY; Shi FD; Xiao BG; Björk J; Hedlund G; Link H
J Neuroimmunol; 1997 Mar; 73(1-2):175-82. PubMed ID: 9058774
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulation with linomide: possible novel therapy for multiple sclerosis.
Abramsky O; Lehmann D; Karussis D
Mult Scler; 1996 Nov; 2(4):206-10. PubMed ID: 9345375
[TBL] [Abstract][Full Text] [Related]
30. Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion.
Abdul-Hai A; Hershkoviz R; Weiss L; Lider O; Slavin S
Int Immunopharmacol; 2005 Feb; 5(2):231-9. PubMed ID: 15652754
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulation of experimental autoimmune myasthenia gravis with linomide.
Karussis DM; Lehmann D; Brenner T; Wirguin I; Mizrachi-Koll R; Sicsic C; Abramsky O
J Neuroimmunol; 1994 Dec; 55(2):187-93. PubMed ID: 7829669
[TBL] [Abstract][Full Text] [Related]
32. Modulation of experimental systemic lupus erythematosus with linomide.
Zandman-Goddard G; George J; Levy Y; Blank M; Slavin S; Shoenfeld Y
Lupus; 1996 Aug; 5(4):328-33. PubMed ID: 8869907
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide.
Karpati T; Karussis D; Abramsky O; Mizrahi-Koll R; Arbell I; Ovadia H
Immunol Lett; 1998 Oct; 63(3):141-5. PubMed ID: 9840682
[TBL] [Abstract][Full Text] [Related]
34. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo.
Christensen UB; Mauricio D; Reimers JI; Andersen HU; Kalland T; Nerup J; Mandrup-Poulsen T
Autoimmunity; 1996; 23(4):257-68. PubMed ID: 8915032
[TBL] [Abstract][Full Text] [Related]
35. Linomide enhances apoptosis in CD4+CD8+ thymocytes.
Harring AC; Xu Z; Andersson G; Hedlund G
Scand J Immunol; 1997 Nov; 46(5):488-94. PubMed ID: 9393631
[TBL] [Abstract][Full Text] [Related]
36. Linomide does not prevent spontaneous autoimmune thyroiditis in NOD mice.
Hartoft-Nielsen ML; Rasmussen AK; Kaas A; Bock T; Buschard K; Feldt-Rasmussen U
Autoimmunity; 2001; 33(2):79-84. PubMed ID: 11264786
[TBL] [Abstract][Full Text] [Related]
37. Multiformic modulation of endotoxin effects by linomide.
Shalev M; Ko A; Gelderman MP; Fortin E; Reed G; Slavin S; Gery I
Clin Immunol; 1999 Dec; 93(3):250-5. PubMed ID: 10600336
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).
Slavin S; Weiss L; Xia W; Gross DJ
Cell Transplant; 1996; 5(6):627-30. PubMed ID: 8951220
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Jönsson S; Andersson G; Fex T; Fristedt T; Hedlund G; Jansson K; Abramo L; Fritzson I; Pekarski O; Runström A; Sandin H; Thuvesson I; Björk A
J Med Chem; 2004 Apr; 47(8):2075-88. PubMed ID: 15056005
[TBL] [Abstract][Full Text] [Related]
40. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.
Condiotti R; Slavin S; Barak V; Nagler A
Leuk Res; 1996 Jan; 20(1):57-63. PubMed ID: 8632678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
